Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management.

Autor:	Xu J; Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China., Zhan Q; Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China., Fan Y; Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China., Lo EKK; School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China., Zhang F; School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China., Yu Y; Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China., El-Nezami H; School of Biological Sciences, University of Hong Kong, Pokfulam 999077, Hong Kong, China.; Institute of Public Health and Clinical Nutrition, School of Medicine, University of Eastern Finland, FI-70211 Kuopio, Finland., Zeng Z; Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing 100034, China.
Jazyk:	angličtina
Zdroj:	Pathogens (Basel, Switzerland) [Pathogens] 2021 Jun 22; Vol. 10 (7). Date of Electronic Publication: 2021 Jun 22.
DOI:	10.3390/pathogens10070782
Abstrakt:	Liver cancer, predominantly hepatocellular carcinoma (HCC), is the third leading cause of cancer-related deaths worldwide. Emerging data highlight the importance of gut homeostasis in the pathogenesis of HCC. Clinical and translational studies revealed the patterns of dysbiosis in HCC patients and their potential role for HCC diagnosis. Research on underlying mechanisms of dysbiosis in HCC development pointed out the direction for improving the treatment and prevention. Despite missing clinical studies, animal models showed that modulation of the gut microbiota by probiotics may become a new way to treat or prevent HCC development.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu